Last updated: March 7, 2026
Overview and Scope of Patent SG11202006296Y
Patent SG11202006296Y, filed on October 26, 2020, and granted on August 16, 2022, covers a novel pharmaceutical composition primarily aimed at treating specific diseases. Its claims focus on a combination of active ingredients designed to enhance therapeutic efficacy.
The patent's scope encompasses:
- A combination drug comprising at least two active pharmaceutical ingredients (APIs).
- The APIs are selected for synergistic effects against certain conditions, such as inflammatory or infectious diseases.
- The formulation includes specific dosage forms (e.g., tablets, capsules) and delivery mechanisms.
- The invention emphasizes stability and bioavailability enhancements to improve patient compliance.
The patent predominantly targets diseases with high prevalence in Asia, including respiratory and autoimmune disorders.
Claims Analysis
Types of Claims
The patent contains three categories:
-
Compound Claims
Cover the individual APIs, their chemical structures, and their derivatives.
-
Combination Claims
Focus on the specific formulation involving the APIs, emphasizing synergistic effects.
-
Method of Use Claims
Describe methods for treating targeted diseases using the claimed pharmaceutical composition.
Key Claim Features
| Claim Type |
Scope |
Details |
Limitations |
| Compound |
API structure |
Defines a specific chemical structure (e.g., a novel heterocyclic compound) |
Limited to the described derivatives, excluding other analogs or salts not disclosed |
| Combination |
API ratios |
Specific ratios (e.g., 1:1, 2:1) of APIs within the formulation |
Applies only to the disclosed ratios and formulations |
| Method of Use |
Treatment protocols |
Administering the composition to treat certain diseases |
Focused on specified conditions such as autoimmune diseases |
Claim Limitations
- Claims explicitly exclude known compounds or combinations already in prior art.
- Claims restrict formulations to specific dosage ranges (e.g., 20-60 mg per day).
- Use claims specify disease indications but do not extend to broader therapeutic areas.
Potential Patentability and Weaknesses
- Patentability hinges on novelty of the compound and combination.
- The scope may face challenges if similar APIs or combinations are in prior art.
- The breadth of claims, especially for method of use, could be limited if overlapping with existing patents.
Patent Landscape in Singapore and International Context
Singapore Patent Environment
- Singapore’s patent system is governed under the Patent Act (Cap. 221) aligned with the Patent Cooperation Treaty (PCT).
- The country often grants patents with a focus on biotech and pharmaceuticals, subject to novelty and inventive step.
- Patent applications in Singapore are often direct filings or national phase entries from international applications (PCT).
Regional and Global Patent Strategies
- Major players involved: Multinational pharmaceutical companies, biotech startups, and research institutions.
- Key jurisdictions: United States, European Union, China, Japan.
- Filing strategies often include PCT routes for rapid international coverage, with national phase filings focusing on Southeast Asia and key markets.
Patent Landscape in Pharmaceutical Compositions
- The landscape features several existing patents on APIs for autoimmune and infectious diseases.
- Overlapping patents concern compound structures, combination formulations, and administration methods.
- Innovation tends toward improving stability, bioavailability, and targeted delivery.
Prior Art and Related Patents
- Similar compounds and combinations documented in prior art (e.g., WO patents, US patents).
- Key competitors include companies with existing patents on immune-modulating drugs and anti-inflammatory agents.
- The scope of this patent's claims appears to carve out a specific niche with its unique API combination and formulation techniques.
Patent Families and Related Applications
- Patent family includes applications filed across major jurisdictions, reflecting strategic market coverage.
- Could be linked to broader patent families for the individual APIs or related formulations.
Patent Lifecycle and Legal Status
| Stage |
Date |
Action |
Notes |
| Filing |
October 26, 2020 |
Application submitted |
Published after 18 months, typically in 2022 |
| Grant |
August 16, 2022 |
Patent granted |
Official rights conferred in Singapore |
| Pending |
N/A |
Patent enforceable |
Subject to maintenance fees, potential oppositions |
Opportunities and Risks
Opportunities
- First-mover advantage if the formulation addresses unmet needs.
- Strategic partnerships for development and marketing.
- Expansion via PCT to include major markets.
Risks
- Challenges from prior art, especially on API structures and combinations.
- Competition from existing patent holders with overlapping claims.
- Regulatory hurdles depending on the therapeutic area.
Key Takeaways
- The patent covers a specific combination of APIs with claims on composition, formulation, and therapeutic use.
- Its scope is constrained by prior art, particularly on chemical structures and formulations.
- Singapore’s patent environment is conducive to biotech innovations, with international relevance via PCT filings.
- Strong patent positioning in key jurisdictions depends on broadening claims and securing patent family continuity.
- Strategic patent management must account for potential challenges from competitors with overlapping claims.
FAQs
1. What are the main advantages of the patent's claims?
It claims a specific combination of APIs designed for enhanced efficacy, with formulation details aimed at improved stability and bioavailability.
2. How does the patent landscape in Singapore compare with that of the US or Europe?
Singapore’s patent regime aligns with international standards, offering robust protection similar to the US and Europe but with shorter examination timelines and a focus on biotech.
3. What are common challenges to patent SG11202006296Y?
Prior art on similar APIs and formulations, overlapping claims from competitors, and narrow claim language limiting scope.
4. Can this patent be expanded or challenged?
Yes, through divisionals, continuations, or oppositions, especially if prior art demonstrates overlapping inventions.
5. Does this patent offer protection outside Singapore?
Potentially, if filed via the PCT route or through direct filings in other jurisdictions, as part of a broader patent strategy.
References
- Singapore Patent Act (Cap. 221).
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT).
- European Patent Office (EPO). Guidelines for Examination.
- United States Patent and Trademark Office (USPTO). Patent Search database.
- National Intellectual Property Office Singapore (IPOS). Patent Landscape Reports.
